Literature DB >> 33641721

Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.

Dipesh Uprety1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33641721     DOI： 10.1016/j.jtho.2020.12.003

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  1 in total

1.  Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.

Authors:  Shannon S Zhang; Sai-Hong Ignatius Ou
Journal:  Lung Cancer (Auckl)       Date:  2022-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.